Novel Rift Valley Fever Virus Vaccines


This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.

Potential Commercial Applications: Competitive Advantages:
  • Rift Valley fever (RVF) virus vaccine development or improvement
  • Prevention of RVF virus infection in livestock and humans
  • Biodefense, biosecurity
 
  • In vivo evidence shows single-dose protection
  • Allows for discrimination between vaccinated and naturally-infected subjects
  • Useful for controlled screening of therapeutic compounds


Development Stage:
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Brian Bird (CDC)  ➽ more inventions...

Cesar Albarino (CDC)  ➽ more inventions...

Stuart Nichol (CDC)  ➽ more inventions...

Thomas Ksiazek (CDC)  ➽ more inventions...


Intellectual Property:
US Pat: 10,064,933 issued 2018-09-04
PCT Pat: 8,673,629 issued 2014-03-18
US Pat: 9,439,935 issued 2016-09-13
US Application No. 14/163,058 filed on 2014-01-24
Additional applications granted and pending

Publications:
Bird BH, et al. PMID 18199647
CDC Fact Sheet: Rift Valley Fever https://www.cdc.gov/vhf/rvf/

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-254-2013-2
Updated: Dec 23, 2013